Tumour Registry Lung Cancer (TLK)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-01-31

Study Completion Date

2016-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Overview of treatment reality in patients with bronchial carcinoma requiring systemic treatment and being treated by office-based oncologists in Germany.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lung Cancer Registry for Lung Cancer Patients

NCT03276429

Lung Cancer

COMPLETED

Epidemiological Study to Describe NSCLC Clinical Management Patterns in Europe. Lung-EPICLIN

NCT00831909

NSCLC

COMPLETED

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

NCT02622581

Metastatic Non-small Cell Lung Cancer (NSCLC) Non-small Cell Lung Cancer Metastatic Non-small Cell Lung Cancer Stage II +3 more

RECRUITING

Thoracic Tumours Register

NCT02941458

Thoracic Tumors

RECRUITING

Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer

NCT01580982

Lung Neoplasms

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The TLK is a prospective, longitudinal, nation wide cohort study that collects data on the treatment reality of patients with NSCLC and SCLC. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, biomarker testing and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Patients are followed until death or for a maximum of 3 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with lung cancer

Patients with lung cancer requiring therapy

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* histologically confirmed Small Cell Lung Cancer (SCLC), Non Small Lung Cancer (NSCLC) or neuroendocrine tumors receiving therapy
* written informed consent
* start of neoadjuvant, adjuvant or first-line therapy no longer than 4 weeks before informed consent